For the quarter ended March 2025, Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported revenue of $839 million, up 17% over the same period last year. EPS came in at $1.06, compared to $0.98 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $793.58 million, representing a surprise of +5.72%. The company delivered an EPS surprise of +7.07%, with the consensus EPS estimate being $0.99.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $250 million versus the two-analyst average estimate of $234.18 million. The reported number represents a year-over-year change of +14.4%.
• Portfolio Receipts- Royalty Receipts- Products- Tysabri: $61 million compared to the $58.87 million average estimate based on two analysts. The reported number represents a change of -11.7% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $46 million compared to the $45.35 million average estimate based on two analysts. The reported number represents a change of -8.1% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Xtandi: $52 million versus $49.97 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +26.8% change.
• Portfolio Receipts- Royalty Receipts- Products- Promacta: $44 million versus $34.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
• Portfolio Receipts- Royalty Receipts- Products- Tremfya: $36 million versus the two-analyst average estimate of $38.91 million. The reported number represents a year-over-year change of -0.5%.
• Portfolio Receipts- Milestones and other contractual receipts: $51 million versus $15.70 million estimated by two analysts on average.
• Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $53 million versus the two-analyst average estimate of $51.98 million. The reported number represents a year-over-year change of +17.9%.
• Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $13 million compared to the $11.32 million average estimate based on two analysts. The reported number represents a change of +26.6% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Total: $788 million compared to the $777.88 million average estimate based on two analysts. The reported number represents a change of +11.9% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Trelegy: $85 million versus the two-analyst average estimate of $84.96 million. The reported number represents a year-over-year change of +20.4%.
• Portfolio Receipts- Royalty Receipts- Products- Spinraza: $13 million versus $12.63 million estimated by two analysts on average.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned +1.5% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.